Q3 EPS Estimate for Axsome Therapeutics Decreased by Analyst

Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) - Equities researchers at William Blair dropped their Q3 2026 earnings per share estimates for Axsome Therapeutics in a report released on Monday, June 9th. William Blair analyst M. Minter now forecasts that the company will post earnings per share of $0.58 for the quarter, down from their prior estimate of $0.60. William Blair has a "Outperform" rating on the stock. The consensus estimate for Axsome Therapeutics' current full-year earnings is ($2.79) per share. William Blair also issued estimates for Axsome Therapeutics' Q4 2026 earnings at $1.20 EPS, FY2026 earnings at $1.56 EPS, FY2027 earnings at $11.43 EPS, FY2028 earnings at $22.36 EPS and FY2029 earnings at $36.22 EPS.

Several other analysts have also recently issued reports on AXSM. Cantor Fitzgerald upgraded Axsome Therapeutics to a "strong-buy" rating in a research note on Wednesday, May 14th. Jefferies Financial Group initiated coverage on Axsome Therapeutics in a research note on Monday, April 7th. They issued a "buy" rating and a $200.00 price objective on the stock. Royal Bank of Canada cut their target price on Axsome Therapeutics from $193.00 to $186.00 and set an "outperform" rating on the stock in a research report on Thursday. Wells Fargo & Company reissued an "overweight" rating and set a $165.00 price target (up from $160.00) on shares of Axsome Therapeutics in a research report on Tuesday, May 6th. Finally, Needham & Company LLC dropped their target price on Axsome Therapeutics from $153.00 to $150.00 and set a "buy" rating on the stock in a research report on Monday. One investment analyst has rated the stock with a hold rating, fifteen have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average target price of $172.33.

Axsome Therapeutics Stock Down 1.7%

AXSM stock traded down $1.83 during trading on Wednesday, reaching $106.25. The stock had a trading volume of 447,175 shares, compared to its average volume of 677,720. Axsome Therapeutics has a 1-year low of $70.52 and a 1-year high of $139.13. The company has a current ratio of 2.11, a quick ratio of 2.04 and a debt-to-equity ratio of 3.22. The company has a market capitalization of $5.23 billion, a P/E ratio of -17.74 and a beta of 0.47. The firm has a fifty day moving average price of $106.32 and a 200 day moving average price of $106.90.

Insider Activity at Axsome Therapeutics

In other Axsome Therapeutics news, COO Mark L. Jacobson sold 25,000 shares of the business's stock in a transaction on Monday, June 9th. The stock was sold at an average price of $110.44, for a total value of $2,761,000.00. Following the transaction, the chief operating officer now owns 5,783 shares of the company's stock, valued at approximately $638,674.52. The trade was a 81.21% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Mark Coleman sold 3,000 shares of the business's stock in a transaction on Tuesday, May 20th. The shares were sold at an average price of $107.49, for a total value of $322,470.00. Following the sale, the director now owns 54,137 shares in the company, valued at approximately $5,819,186.13. The trade was a 5.25% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 72,423 shares of company stock worth $7,711,619 over the last quarter. Company insiders own 22.30% of the company's stock.

Institutional Trading of Axsome Therapeutics

Several institutional investors have recently added to or reduced their stakes in the business. Caitong International Asset Management Co. Ltd bought a new position in Axsome Therapeutics in the 1st quarter worth $25,000. Quantbot Technologies LP purchased a new stake in Axsome Therapeutics during the first quarter valued at $31,000. NBC Securities Inc. bought a new position in shares of Axsome Therapeutics in the 1st quarter worth approximately $31,000. AlphaQuest LLC purchased a new stake in shares of Axsome Therapeutics in the 1st quarter worth $38,000. Finally, Neo Ivy Capital Management bought a new position in shares of Axsome Therapeutics during the 1st quarter valued at approximately $41,000. 81.49% of the stock is currently owned by hedge funds and other institutional investors.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.